John P. Butler sold $303k of AKBA
CEO and President at Akebia Therapeutics, Inc.. 144,250 shares at an average of $2.10, traded Feb 3, 2025, filed Feb 4, 2025.
Score components
- +25RoleCEO
- +14Trade size$303k at market
- 0Share of holdings soldSold 5.2% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-000917, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | AGrant or award Common Stock10b5-1 | +701,000 | $0.00 | $0 | 2,748,580 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -46,268 | $2.10 | $97k | 2,702,312 | Feb 4, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -97,982 | $2.10 | $206k | 2,604,330 | Feb 4, 2025 |
| Jan 31, 2025 | AGrant or award Performance Stock Unitsderivative10b5-1 | +350,500 | $0.00 | $0 | 350,500 | Feb 4, 2025 |
| Jan 31, 2025 | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +1,051,400 | $0.00 | $0 | 1,051,400 | Feb 4, 2025 |
Related signals
Other insiders at Akebia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Akebia Therapeutics, Inc. | Erik Ostrowski SVP, CFO, CBO & Treasurer | $152k 41,314 shares | -8% | |
| 0Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $60k 15,000 shares | -5% | |
| 1Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $47k 13,334 shares | -5% | |
| 3Weak | Akebia Therapeutics, Inc. | Steven Keith Burke SVP, Chief Medical Officer | $13k 7,144 shares | -1% | |
| 22Weak | Akebia Therapeutics, Inc. | John P. Butler CEO and President | $85k 46,409 shares | -2% | |
| 25Weak | Akebia Therapeutics, Inc. | Nicholas Grund Chief Commercial Officer | $117k 55,621 shares | -11% | |
| 18Weak | Akebia Therapeutics, Inc. | Richard C Malabre SVP, Chief Accounting Officer | $63k 30,202 shares | -10% | |
| 20Weak | Akebia Therapeutics, Inc. | Steven Keith Burke SVP, Chief Medical Officer | $106k 50,506 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.